2023
Disparities in stage at diagnosis among breast cancer molecular subtypes in China
Zeng H, Wu S, Ma F, Ji J, Lu L, Ran X, Shi J, Li D, An L, Zheng R, Zhang S, Chen W, Wei W, He Y, He J. Disparities in stage at diagnosis among breast cancer molecular subtypes in China. Cancer Medicine 2023, 12: 10865-10876. PMID: 36951474, PMCID: PMC10225199, DOI: 10.1002/cam4.5792.Peer-Reviewed Original ResearchConceptsBody mass indexBreast cancerMolecular subtypesMass indexFamily historyFirst primary invasive breast cancerFirst primary breast cancerPrimary invasive breast cancerHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Triple-negative breast cancerBreast cancer molecular subtypesEnd Results (SEER) databaseBreast cancer treatment strategiesGrowth factor receptor 2Primary breast cancerInvasive breast cancerOverweight/obeseStage breast cancerBreast cancer patientsBreast cancer casesCancer molecular subtypesFactor receptor 2Cancer treatment strategies
2022
Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
Yao L, Jia G, Lu L, Ma W. Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies? Current Oncology 2022, 29: 4902-4913. PMID: 35877249, PMCID: PMC9320700, DOI: 10.3390/curroncol29070389.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapyBreast cancer patientsCancer patientsEfficacy of NACHuman leukocyte antigen-DR isotypeInitiation of therapyTumor-infiltrating lymphocytesBenefits of treatmentTumor-associated macrophagesOncotype DXMolecular testingPatientsDecreased levelsCancer cellsChemotherapyTreatmentMammaPrintSurgeryLymphocytesTherapyTumorsMacrophages
2021
Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival
Li W, Amei A, Bui F, Norouzifar S, Lu L, Wang Z. Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival. Cancers 2021, 13: 2879. PMID: 34207556, PMCID: PMC8228363, DOI: 10.3390/cancers13122879.Peer-Reviewed Original ResearchT cell activationNeoantigen expressionChi-squared testOverall survivalBreast cancerMultivariable Cox proportional hazards modelsMultivariable Cox regression modelsCox proportional hazards modelImproved overall survivalT-cell statusT cell exhaustionBreast cancer patientsKaplan-Meier survivalBreast cancer survivalCox regression modelClinical-pathological variablesReceptor-positive subgroupCancer immunotherapy efficacyProportional hazards modelPearson's chi-squared testTumor-specific somatic mutationsSpearman correlation analysisImmunotherapy efficacyPathological variablesPatient survival
2020
Regulation and characterization of tumor-infiltrating immune cells in breast cancer
Dai Q, Wu W, Amei A, Yan X, Lu L, Wang Z. Regulation and characterization of tumor-infiltrating immune cells in breast cancer. International Immunopharmacology 2020, 90: 107167. PMID: 33223469, PMCID: PMC7855363, DOI: 10.1016/j.intimp.2020.107167.Peer-Reviewed Original ResearchConceptsTumor-infiltrating immune cellsT cell activation statusImmune cellsCell activation statusT cell activationPatient survivalM2 macrophagesT cellsBreast cancerCell activationT cell peripheral toleranceTumor-infiltrating B cellsMultivariate Cox regression modelActivation statusBreast cancer patient survivalEffector T cellsT cell subsetsBreast cancer patientsImmune cell infiltrationAbundant plasma cellsCox regression modelKaplan-Meier survivalImmune cell typesMolecular pathwaysCancer patient survivalMeta-analysis of the clinicopathological significance of miRNA-145 in breast cancer
Lv P, Zhang Z, Hou L, Zhang Y, Lu L, Wang C, Shi F. Meta-analysis of the clinicopathological significance of miRNA-145 in breast cancer. Bioscience Reports 2020, 40: bsr20193974. PMID: 32869851, PMCID: PMC7502658, DOI: 10.1042/bsr20193974.Peer-Reviewed Original ResearchConceptsMiR-145 expressionBreast cancer patientsBreast cancerStandardized mean differenceBreast cancer tissuesAdjacent normal tissuesMiR-145Cancer patientsTumor suppressor miRNACancer tissuesLow expressionNormal tissuesLymph node metastasisUnfavorable prognostic factorLargest tumor diameterSuppressor miRNALower miR-145Normal breast tissueWeb of ScienceNode metastasisPrognostic factorsHealthy womenTumor diameterClinicopathological significanceEligible studiesInterplay of tRNA-Derived Fragments and T Cell Activation in Breast Cancer Patient Survival
Shan N, Li N, Dai Q, Hou L, Yan X, Amei A, Lu L, Wang Z. Interplay of tRNA-Derived Fragments and T Cell Activation in Breast Cancer Patient Survival. Cancers 2020, 12: 2230. PMID: 32785169, PMCID: PMC7466003, DOI: 10.3390/cancers12082230.Peer-Reviewed Original ResearchT cell activationBreast cancer patient survivalCancer patient survivalOverall survivalCell activationBreast cancerExpression of tRFsImproved survivalPatient survivalMultivariate Cox regression modelBreast cancer patientsCox regression modelKaplan-Meier survivalSpearman correlation analysisEffector CD8Cytotoxic functionCancer patientsExhaustion groupsTherapeutic targetCancer progressionCancerSurvivalGene co-expression network analysisActivation groupTRNA-derived fragments
2019
BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer
Lu L, Huang H, Zhou J, Ma W, Mackay S, Wang Z. BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer. BMC Cancer 2019, 19: 387. PMID: 31023256, PMCID: PMC6482542, DOI: 10.1186/s12885-019-5595-3.Peer-Reviewed Original ResearchConceptsT cell activation statusCell activation statusPatient survivalT cell activationBreast cancerActivation statusCCND1 levelsCell activationT cell activation scoreCCND1 expressionKaplan-Meier survival curvesAdjusted hazard ratioCCND1 expression levelsBreast cancer patient survivalImmune checkpoint blockadeBetter overall survivalBreast cancer patientsCox regression modelCancer patient survivalT cell recognitionBRCA1 levelsBRCA1 mRNA expressionCheckpoint blockadeHazard ratioOverall survival
2018
Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer
Chen Q, Yao L, Burner D, Minev B, Lu L, Wang M, Ma W. Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer. Clinical And Translational Oncology 2018, 21: 433-442. PMID: 30218306, DOI: 10.1007/s12094-018-1941-1.Peer-Reviewed Original ResearchConceptsEpithelial membrane protein-2MDA-MB-231 cellsBreast cancerBreast cancer cellsNovel biomarkersMCF7 cellsCancer cellsAnti-pan cytokeratinPrimary breast cancerBreast cancer patientsMesenchymal transition eventsPatient blood samplesTumor cell recoveryFlow cytometric assayCTC countCancer patientsHealthy donorsBlood samplesMembrane protein 2Cytometric assayTumor cellsEMP2 expressionCancerCell spikingBiomarkers
2017
Elevated T cell activation score is associated with improved survival of breast cancer
Lu L, Bai Y, Wang Z. Elevated T cell activation score is associated with improved survival of breast cancer. Breast Cancer Research And Treatment 2017, 164: 689-696. PMID: 28488141, DOI: 10.1007/s10549-017-4281-x.Peer-Reviewed Original ResearchConceptsT cell activation scoreBreast cancer patientsOverall survivalPatients' overall survivalCancer patientsImproved survivalPD-1Activation scoresBreast cancerCell death-1 receptorLow PD-1 expressionMultivariate Cox regression analysisT-lymphocyte antigen-4Kaplan-Meier survival curvesT cell activation statusDeath-1 receptorPD-1 expressionEffector T cellsImmune checkpoint blockadeCox regression analysisPoor overall survivalCox regression modelT cell functionActivation groupCell activation status
2015
Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis
Wang Z, Katsaros D, Shen Y, Fu Y, Canuto EM, Benedetto C, Lu L, Chu WM, Risch HA, Yu H. Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis. PLOS ONE 2015, 10: e0136246. PMID: 26287798, PMCID: PMC4546117, DOI: 10.1371/journal.pone.0136246.Peer-Reviewed Original ResearchConceptsBreast cancer prognosisCancer prognosisGene expression signaturesExpression signaturesPoor disease-free survivalDisease-free survivalBreast cancer patientsBreast cancer cell linesBreast cancer progressionMDA-MB-468Tumor cell growthMDA-MB-231Multiple gene expression signaturesCancer cell linesAggressive tumorsCancer patientsClinical significanceDisease outcomeTumor featuresClinical implicationsPrognosisCancer progressionBiologic relevanceHigh expressionCell proliferation
2011
Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1
Zeng H, Irwin ML, Lu L, Risch H, Mayne S, Mu L, Deng Q, Scarampi L, Mitidieri M, Katsaros D, Yu H. Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1. Breast Cancer Research And Treatment 2011, 133: 127-135. PMID: 21837478, DOI: 10.1007/s10549-011-1716-7.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChromosomal Proteins, Non-HistoneDNA MethylationEpigenesis, GeneticFemaleGene ExpressionGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansKaplan-Meier EstimateMotor ActivityRepressor ProteinsTumor Suppressor ProteinsConceptsBreast cancer patientsBreast cancer survivalCancer patientsPhysical activityOverall survivalSurvival outcomesTumor suppressor geneCancer survivalHormone receptor-positive tumorsModerate-intensity aerobic exerciseHigh expressionBreast cancer deathsReceptor-positive tumorsRandomized clinical trialsExercise-related changesSuppressor genePeripheral blood leukocytesBreast cancer diagnosisGene expressionDisease recurrenceAerobic exerciseCancer deathClinical trialsTumor featuresBlood leukocytesTelomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome
Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, Mitidieri M, Katsaros D, Yu H. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Research 2011, 13: r56. PMID: 21645396, PMCID: PMC3218945, DOI: 10.1186/bcr2893.Peer-Reviewed Original ResearchConceptsEndocrine therapyDisease outcomeAdjuvant treatmentTelomerase expressionBetter survival outcomesDisease-free survivalHormone receptor statusBreast cancer patientsRisk of deathTelomere lengthHigh telomeraseCause-specific mortalityBreast cancer prognosisBreast cancer cellsCancer cell resistanceHigh telomerase expressionOverall survivalPatient ageDisease recurrenceReceptor statusHistological typeAggressive diseaseSurvival outcomesDisease stageCancer patients
2010
Let-7a regulation of insulin-like growth factors in breast cancer
Lu L, Katsaros D, Zhu Y, Hoffman A, Luca S, Marion CE, Mu L, Risch H, Yu H. Let-7a regulation of insulin-like growth factors in breast cancer. Breast Cancer Research And Treatment 2010, 126: 687-694. PMID: 20848182, DOI: 10.1007/s10549-010-1168-5.Peer-Reviewed Original ResearchConceptsIGF expressionBreast cancerOvarian cancerInsulin-like growth factorDisease-free survivalCancer cellsAction of IGFBreast cancer patientsExpression of IGFHigh-grade tumorsIGF-II expressionPR-negative cancerLet-7aQuantitative methylation-specific PCRBreast cancer samplesOverall survivalFavorable prognosisPatient survivalCancer patientsGrade tumorsIGF mRNAsMethylation-specific PCRDisease featuresCancerCancer samples
2008
TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival
Mu L, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Yu H. TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. British Journal Of Cancer 2008, 99: 1357-1363. PMID: 18827819, PMCID: PMC2570529, DOI: 10.1038/sj.bjc.6604689.Peer-Reviewed Original ResearchConceptsHigher TGF-β1TGF-β1 genotypesTGF-β1T genotypeHazard ratioBreast cancerBreast tumorsProportional hazards regression analysisLower TGF-β1Early-stage diseaseHazards regression analysisBreast cancer patientsLate-stage diseaseShorter overall survivalFresh tumor samplesTGF-β1 concentrationsBreast cancer progressionClinical characteristicsIGFBP-3Overall survivalDisease recurrenceReceptor statusPatient survivalSurvival outcomesDisease stage